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Abstract: 
 In this report, our early experience with screening, monitoring and coordinating IVF utilising 
gestational carrier treatment is described. Although congenital and iatrogenic etiologies for uterine 
factor infertility manifest distinctly different reasons for considering a gestational carrier approach, 
we outline a unified management strategy for both conditions. One patient had congenital absence 
of the uterus and proximal vagina (Mayer-Rokitansky-Kˆ…ster-Hauser syndrome variant), while 
another patient presented posthysterectomy and adjuvant brachytherapy for invasive squamous 
cervical carcinoma. Conception was established for both patients, the first pregnancies to be 
achieved using an IVF/gestational carrier technique in Ireland. As demonstrated here, selected 
patients with at least one intact ovary who suffer from uterine factor infertility can be excellent 
candidates for IVF with embryo transfer to a carefully screened gestational carrier. The role of 
individual and group counselling is reviewed; professional legal advice is prudent in complex cases.  
Introduction: 
 Increased access to the advanced reproductive technologies has enabled a coordinated treatment 
sequence whereby a woman without a uterus has the potential to use her own gametes to create 
genetically-related embryos, which may then be transferred to a surrogate host with a functional 
uterus (â€œgestational carrierâ€•). Although the successful application of this technology only 
emerged in modern times, the closely allied concept of surrogacy is recorded near the dawn of 
written history1 . While the unfortunate diagnosis of absent or dysfunctional uterus can exist in 
several pathological settings, for the reproductive endocrinologist the clinical approach is fairly 
consistent as described here.  
Case 1  
A 29 year old non-smoking Caucasian nulligravida with a prior diagnosis of node-positive squamous 
carcinoma of the cervix (stage IB) sought reproductive endocrinology consultation with her husband. 
In otherwise good general health, the patient already had surgery and was under the care of a 
gynaecologic oncologist in preparation for further therapy. The patient wished to begin fertility 
treatment quickly to â€œsave the eggs, if we canâ€•. The husbandâ€™s semen analysis and 
laboratory tests were all normal. In coordination with the oncology team, our centre recommended 
immediate screening in advance of controlled ovarian hyperstimulation for IVF. However, this would 
be followed by empiric cryopreservation of all embryos with a view to perform embryo transfer only 
after all adjuvant radio- and/or chemotherapy had concluded and oncology clearance had been 
obtained. The embryo transfer would then be performed on the patientâ€™s sister, who volunteered 
to carry the pregnancy.  
The patient and her partner agreed with and understood this rationale for treatment, designed to 
maintain fertility potential without compromising effectiveness of her cervical cancer treatment. The 
sister (age 25) was in good general health, did not smoke, took no regular medications, and had a 
four year-old son of her own. Screening commenced on her in parallel with legal consultations to 
develop a â€surrogacy contractâ€™ protecting the interests of all parties concerned. Individual and 
group counselling was also undertaken with an emphasis on the procedure itself, the possible 
outcomes, including the likelihood of treatment failure (i.e., no pregnancy or miscarriage), and the 
impact these outcomes might have on the lives of all involved. Written informed consent was 
obtained from all parties. 
 Baseline vital signs were normal. Blood type was O positive, rubella immunity was confirmed, and all 
STD serologies were negative. Pituitary downregulation was achieved with intranasal buserelin 
(400mcg t.i.d.). No oral contraceptive pills were used. Ovulation induction followed a combined 
225IU FSH + 75IU hMG/day regimen, as reported previously2 . A total of 2100IU gonadotropins was 
consumed during stimulation, retrieving ten oocytes after a seven day follicular recruitment phase. 
Oocyte quality was poor; only one 2pn embryo was suitable for cryopreservation after conventional 
insemination. Two days later, the patient returned to her oncologist to begin brachytherapy. For the 
sister, all laboratory tests, a saline sonogram and trial embryo transfer were completed over the 
next 10 months. Approximately one year after the initial single embryo was frozen, the carrier 
(sister) returned for planned FET. Unfortunately the single cryopreserved embryo did not survive 
thaw, thus no transfer was done. Because of the intervening adjuvant oncology therapy sustained by 
the patient (now disease-free for 12 months), it was not recommended that further ovulation 
induction cycles be performed using her native oocytes.  
Soon afterward the sister again proposed her assistance, although going forward she volunteered to 
be the gestational carrier as well as known oocyte donor for the commissioning couple. Further 
counselling was mandatory as informed consent was again obtained from the patient, her husband 
and sister. Ovarian reserve testing confirmed the suitability of the sister to serve as an oocyte donor, 
and further psychological clearance was obtained. Formal contracts describing the revised treatment 
were reconfigured with input from solicitors. For the sister (donor-carrier), her pituitary 
downregulation was accomplished with low-dose oral contraceptives plus intranasal buserelin 
(400mcg t.i.d.). A total of 3375IU of gonadotropins were used as a combined hMG/FSH protocol. 
Ovarian morphology was used to determine cycle response and serum E2 levels were not measured.  
After a nine day monitored ovulation induction phase, 12 ocytes were retrieved and the following 
day a 30-day course of 400mg/day intravaginal cyclogest (Actavis Ltd; Devon, UK) with 50mg/day 
I.M. gestone (Ferring Inc; Dublin, Ireland) was initiated. Seven oocytes advanced to 2pn stage after 
conventional insemination, and the gestational carrier returned for a twoblastocyst transfer on day 
five. Three blastocysts were of sufficient quality for cryopreservation. The carrier had a positive 
qualitative hCG test 12 days after embryo transfer, and a twin (dichorionic) intrauterine pregnancy 
was confirmed on transvaginal sonogram approximately 20 days later. Healthy twins (male/female) 
were delivered at 36 weeksâ€™ gestation by Caesarean, and were discharged from hospital to the 
commissioning mother and father after four days.  
Case 2  
A 31 year old non-smoking Caucasian nulligravida with primary amenorrhea presented with her 
husband for fertility treatment. Both were in good general health and had no medical complaint. 
Although the diagnosis of Mayer-Rokitansky-Kˆ…ster-Hauser syndrome was made during an earlier 
evaluation for delayed menarche, this was subsequently refined to include unilateral (left) ovarian 
agenesis and absent left kidney. She had no gross skeletal, cardiac or otic defects. Serum FSH, E2, 
and P4 (random) were 6.0mIU/ml, 393 pmol/L, and 23 nmol/L respectively. TSH and prolactin were 
normal. The patient had considered vaginoplasty six years earlier, and a normal 46,XX karyotype was 
confirmed during that evaluation. She had a satisfactory response to a graduated vaginal dilator 
programme, but abandoned this for personal reasons. She also declined consultation for neovaginal 
surgery when she became sexually active. At our centre, physical examination revealed a well-
developed phenotypic female although the vaginal canal ended in a blind pouch and was slightly 
shortened. No cervix was present and only the right ovary was visualised on transvaginal sonogram. 
Vital signs were normal.Blood type was B positive, rubella immunity was confirmed, and all STD 
serologies were negative.  
The husband (age 29) was a non-smoker and had never commissioned a pregnancy with any prior 
partners; his laboratory tests were all normal. Semen analysis showed an overall sperm 
concentration of 24 million/ml, 58% motility, and normal forms morphology >10% (WHO criteria, 
1992). The wifeâ€™s sister (age 38) suggested herself as a gestational carrier. The sister was a non-
smoker, in good general health, and had two biological children of her own conceived without 
medical assistance. After individual and group counselling, the patient elected to proceed with 
controlled ovarian hyperstimulation and IVF, with her sister undergoing embryo transfer. A saline-
infusion sonogram was performed on the sister and confirmed normal intrauterine contours. All 
laboratory tests on the sister were normal. Given the limited ovarian reserve usually associated with 
unilateral absence of the ovary, the likelihood of cycle cancellation due to poor follicular response 
was acknowledged. Use of donor gametes was declined, however.  
Written informed consent was obtained from all parties, and a gestational carrier contract was 
executed. Since the patient had no uterus and therefore could not menstruate, cycle day 
determinations using conventional methods were impossible. A commercially available urinary LH 
test kit was used every other day to determine day of ovulation, and low-dose OCPs were started 
approximately 14 days after detection of surge. Intranasal buserelin (400mcg t.i.d.) was started on 
OCP day 12 to complete pituitary downregulation. Follicular recruitment followed a combined 
FSH/hMG regimen, with a total of 5100IU of gonadotropin consumed over a 12 day stimulation 
interval. Cycle response was monitored via ovarian morphology only; no serum E2 levels were 
obtained. Ovulation was induced via 10,000IU hCG administered subcutaneously3 with transvaginal 
sonogram-guided oocyte retrieval performed 36 hours later. A total of six oocytes were collected (all 
from R ovary). Four oocytes advanced to the 2pn stage after conventional insemination and all 
progressed to blastocyst by day 5 in culture. All four blastocysts were cryopreserved to facilitate 
embryo transfer with the gestational carrier.  
 Eight weeks later, two blastocysts were thawed and the carrier underwent a two-blastocyst FET 
under direct transabdominal ultrasound guidance. 400mg intravaginal cyclogest (Actavis Ltd; Devon, 
UK) with 50mg I.M. gestone (Ferring Inc; Dublin, Ireland) x 30 days was given for luteal support 
beginning one week prior to embryo transfer. A qualitative hCG test was scheduled for 12 days after 
transfer. All progesterone was discontinued when a negative pregnancy was registered. Three 
months later using an identical embryo transfer and supplementary progesterone protocol, the 
carrier underwent another FET for the two remaining blastocysts. A positive qualitative hCG assay 
was obtained two weeks later. By cycle day 50, transvaginal sonogram revealed an intrauterine twin 
(dichorionic) pregnancy and both sacs demonstrated positive cardiac action. Now in the second 
trimester, the twin pregnancy continues with an uncomplicated obstetrical course.  
Discussion  
Before the arrival of the advanced reproductive technologies, the dream to achieve a pregnancy by 
women with intact ovaries but absent uterus could never be realised. More than 20 years ago, the 
first livebirth from IVF followed by embryo transfer to a gestational carrier was reported4 and 
several centres have presented their experience with this treatment since then5-9. While most 
clinics have the technical capacity to offer gestational carrier treatments, this highly coordinated 
therapy constitutes only a small number of cycles even in the busiest IVF programmes10. Gestational 
surrogacy is lawfully permitted only in a few European countries11. Although legal in Ireland for 
several years, its clinical deployment here awaited assent from the RCPIâ€™s Institute of 
Obstetricians & Gynaecologists, which came in 2006. The IVF patients presented in the current 
report embarked on treatment shortly thereafter, and are believed to be the first in Ireland to 
conceive using this treatment. 
 Select patients presenting with gonadal function but no uterus may be offered IVF utilising native 
oocytes with gestational carrier treatment. However, our two cases brought still further challenges 
as ovarian reserve was limited either by unilateral ovarian agenesis or by the negative impact of 
radiotherapy (for cervical carcinoma). The patients were counselled about the significance of 
impaired ovarian reserve and advised that their risk of cycle cancellation would be increased. Our 
patient who underwent radiation therapy for malignancy had a sister who served as her gestational 
carrier and also ultimately provided gametes (after an initial IVF attempt using the patientâ€™s own 
eggs had failed). In this circumstance, since the sister was both oocyte donor and gestational carrier, 
additional counselling and a highly detailed informed consent developed by an experienced solicitor 
were indicated. These pregnancies (and healthy twin delivery, in one case) represent a meaningful 
remedy to the challenges of family building encountered by women without a functional uterus. 
Notwithstanding the spectrum of etiologies resulting in this unusual condition, the cases described 
here illustrate how IVF with a gestational carrier approach can serve as a therapeutic pathway to 
accomplish conception. 
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